SpringerLink
Log in

What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?

  • Leukemia (PH Wiernik, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Daunorubicin dose intensification for induction in acute myeloid leukemia has been reported as an effective strategy in recent trials to improve patient outcomes without worsening treatment-related toxicity. Based on available evidence, 90 mg/m2 of daunorubicin given for three consecutive days (cumulative dose 270 mg/m2) as a part of the “7 + 3” induction regimen along with cytarabine is the most effective dose to achieve a complete remission as well as improve survival in patients who can tolerate it. This should be considered strongly in younger patients (less than 65 years of age and especially in those less than 50 years) irrespective of cytogenetic risk (likely more beneficial for favorable and intermediate risk) or molecular mutations (definitely in those with NPM1 or FLT3-ITD mutations). Among older acute myeloid leukemia (AML) patients (>65 years), using a higher dose of daunorubicin may not improve survival. It is unclear if daunorubicin at 60 mg/m2 for 3 days is as efficacious as the 90 mg/m2 dose but may be used when there are concerns about tolerability of the higher dose. Although 90 mg/m2 has no more adverse effects compared to 45 mg/m2 of daunorubicin, increasing dosage beyond a cumulative dose of 330 mg/m2 is detrimental due to increase in early mortality. Idarubicin 12 mg/m2 for 3 days is an alternative with the possibility of better long-term outcomes. Elderly patients with AML and those with unfavorable cytogenetics, secondary, or treatment-related disease remain challenging to treat. All patients should be treated on clinical trials when available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Yates JW, Wallace Jr HJ, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57(4):485–8.

    CAS  PubMed  Google Scholar 

  2. Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53–61. doi:10.1182/blood-2015-08-604520.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Weil M, Glidewell OJ, Jacquillat C, Levy R, Serpick AA, Wiernik PH, et al. Daunorubicin in the therapy of acute granulocytic leukemia. Cancer Res. 1973;33(5):921–8.

    CAS  PubMed  Google Scholar 

  4. Lichtman MA. A historical perspective on the development of the cytarabine (7 days) and daunorubicin (3 days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7 + 3. Blood Cells Mol Dis. 2013;50(2):119–30. doi:10.1016/j.bcmd.2012.10.005.

    Article  CAS  PubMed  Google Scholar 

  5. Bernard J, Jacquillat C, Boiron M, Najean Y, Seligmann M, Tanzer J, et al. Trial of treatment of acute lymphoblastic and myeloblastic leukemias by a new antibiotic: rubidomycin (RP 13,057). Study of 61 cases. Presse Med. 1967;75(19):951–5.

    CAS  PubMed  Google Scholar 

  6. Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981;58(6):1203–12.

    CAS  PubMed  Google Scholar 

  7. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982;60(2):454–62.

    CAS  PubMed  Google Scholar 

  8. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 study. Blood. 2011;117(8):2358–65. doi:10.1182/blood-2010-03-273243.

    Article  CAS  PubMed  Google Scholar 

  9. Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol. 2010;28(5):808–14. doi:10.1200/JCO.2009.23.2652.

    Article  CAS  PubMed  Google Scholar 

  10. Appelbaum FR, Dahlberg S, Thomas ED, Buckner CD, Cheever MA, Clift RA, et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med. 1984;101(5):581–8.

    Article  CAS  PubMed  Google Scholar 

  11. Castaigne S, Chevret S, Archimbaud E, Fenaux P, Bordessoule D, Tilly H, et al. Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood. 2004;104(8):2467–74. doi:10.1182/blood-2003-10-3561.

    Article  CAS  PubMed  Google Scholar 

  12. Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of cancer and leukemia group B study 9621. J Clin Oncol. 2004;22(21):4290–301. doi:10.1200/JCO.2004.11.106.

    Article  CAS  PubMed  Google Scholar 

  13. •• Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015;125(25):3878–85. doi:10.1182/blood-2015-01-623447. Large randomized trial comparing daunorubicin 90 with 60 mg/m2 showed detrimental effect of cumulative dose greater than 330 mg/m2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. •• Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, et al. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016;127(12):1551–8. doi:10.1182/blood-2015-07-657403. Long-term follow-up of ECOG E1900 trial of younger (age <60) AML patients which showed benefit from daunorubicin 90 mg/m2 over 45 mg/m2 for all cytogenetic and molecular groups.

    Article  CAS  PubMed  Google Scholar 

  15. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249–59. doi:10.1056/NEJMoa0904544.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lee JH, Joo YD, Kim H, Bae SH, Kim MK, Zang DY, et al. A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood. 2011;118(14):3832–41. doi:10.1182/blood-2011-06-361410.

    Article  CAS  PubMed  Google Scholar 

  17. Lowenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235–48. doi:10.1056/NEJMoa0901409.

    Article  PubMed  Google Scholar 

  18. Bertoli S, Bories P, Bene MC, Daliphard S, Lioure B, Pigneux A, et al. Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group. Haematologica. 2014;99(1):46–53. doi:10.3324/haematol.2013.091819.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Buchner T, Hiddemann W, Wormann B, Loffler H, Gassmann W, Haferlach T, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML cooperative group. Blood. 1999;93(12):4116–24.

    CAS  PubMed  Google Scholar 

  20. Buchner T, Schlenk RF, Schaich M, Dohner K, Krahl R, Krauter J, et al. Acute myeloid leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML intergroup. J Clin Oncol. 2012;30(29):3604–10. doi:10.1200/JCO.2012.42.2907.

    Article  PubMed  Google Scholar 

  21. Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995;86(2):457–62.

    CAS  PubMed  Google Scholar 

  22. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–60. doi:10.1182/blood-2013-01-466706.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Buchner T, Hiddemann W, Berdel WE, Wormann B, Schoch C, Fonatsch C, et al. 6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol. 2003;21(24):4496–504. doi:10.1200/JCO.2003.02.133.

    Article  PubMed  Google Scholar 

  24. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood. 1992;79(8):1924–30.

    CAS  PubMed  Google Scholar 

  25. Foon KA, Zighelboim J, Yale C, Gale RP. Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia. Blood. 1981;58(3):467–70.

    CAS  PubMed  Google Scholar 

  26. Khattry N, Kumar R, Patel C, Raina V, Sharma A, Chandra P, et al. Comparison of 2 doses of daunorubicin(45 mg/m2 vs 60 mg/m2) in induction therapy of patients of de novo acute myeloid leukemia. J Clin Oncol. 2006;24(90180):6581. doi: 10.1200/jco.2006.24.90180.6581

  27. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–89. doi:10.1056/NEJMoa1112304.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Prebet T, Bertoli S, Delaunay J, Pigneux A, Delabesse E, Mozziconacci MJ, et al. Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. Haematologica. 2014;99(10):e185–7. doi:10.3324/haematol.2014.109827.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Devillier R, Bertoli S, Prebet T, Huguet F, Etienne A, Charbonnier A, et al. Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics. Am J Hematol. 2015;90(2):E29–30. doi:10.1002/ajh.23884.

    Article  CAS  PubMed  Google Scholar 

  30. Reagan JL, Sullivan MR, Winer ES, Lansigan F, Cardin MS, Castillo JJ. Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: a multicenter retrospective study. Leuk Res. 2015;39(8):812–7. doi:10.1016/j.leukres.2015.04.015.

    Article  CAS  PubMed  Google Scholar 

  31. Vaezi M, Bahar B, Mousavi A, Yaghmai M, Kasaeian A, Souri M, et al. Comparison of 60 and 80 mg/m2 of daunorubicin in induction therapy of acute myeloid leukaemia. Hematol Oncol. 2015; doi:10.1002/hon.2236.

    Google Scholar 

  32. •• Burnett AK, Russell NH, Hills RK. Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. Blood. 2016;128(3):449–52. doi:10.1182/blood-2016-04-712091. Updated analysis of AML17 trial which showed significant benefit of high daunorubicin dose intensification in FLT3-mutated AML

    Article  CAS  PubMed  Google Scholar 

  33. Gong Q, Zhou L, Xu S, Li X, Zou Y, Chen J. High doses of daunorubicin during induction therapy of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis of prospective clinical trials. PLoS One. 2015;10(5):e0125612. doi:10.1371/journal.pone.0125612.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1302–11.

    Article  CAS  PubMed  Google Scholar 

  35. Frohling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Dohner K, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006;108(10):3280–8. doi:10.1182/blood-2006-04-014324.

    Article  CAS  PubMed  Google Scholar 

  36. Anderson JE, Kopecky KJ, Willman CL, Head D, O'Donnell MR, Luthardt FW, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a southwest oncology group study. Blood. 2002;100(12):3869–76. doi:10.1182/blood-2001-12-0354.

    Article  CAS  PubMed  Google Scholar 

  37. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–74. doi:10.1182/blood-2009-07-235358.

    Article  PubMed  Google Scholar 

  38. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991;77(8):1666–74.

    CAS  PubMed  Google Scholar 

  39. Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a southeastern cancer study group study. J Clin Oncol. 1992;10(7):1103–11.

    CAS  PubMed  Google Scholar 

  40. Wiernik PH, Banks PL, Case Jr DC, Arlin ZA, Periman PO, Todd MB, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79(2):313–9.

    CAS  PubMed  Google Scholar 

  41. Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA groups study AML-10. J Clin Oncol. 2009;27(32):5397–403. doi:10.1200/JCO.2008.20.6490.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. • Teuffel O, Leibundgut K, Lehrnbecher T, Alonzo TA, Beyene J, Sung L. Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol. 2013;161(2):192–203. doi:10.1111/bjh.12233. Meta-analysis of anthracycline induction regimens in AML comparing different daunorubicin dosing as well as daunorubicin versus other anthracyclines

    Article  CAS  PubMed  Google Scholar 

  43. • Gardin C, Chevret S, Pautas C, Turlure P, Raffoux E, Thomas X, et al. Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older. J Clin Oncol. 2013;31(3):321–7. doi:10.1200/JCO.2011.40.3642. Prognostic analysis of ALFA 9801 and 9803 trials comparing idarubicin versus daunorubicin in older (age >50) AML patients.

    Article  CAS  PubMed  Google Scholar 

  44. Stone RM, Sanford BL, Geyer S, Bloomfield CD, Dohner K, Thiede C et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]). ASH 2015: Blood; 2015.

  45. Lancet JE, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK et al. Final results of a phase III randomized trial of CPX-351 versus 7 + 3 in older patients with newly diagnosed high risk (secondary) AML. ASCO 2016; Chicago: J Clin Oncol; 2016.

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, Rochester, MN, USA

    Priyanka Pophali MD & Mark Litzow MD

Authors
  1. Priyanka Pophali MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Litzow MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Litzow MD.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Leukemia

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pophali, P., Litzow, M. What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?. Curr. Treat. Options in Oncol. 18, 3 (2017). https://doi.org/10.1007/s11864-017-0446-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-017-0446-4

Keywords

Search

Navigation